Delivery Order SPE2DB24D2205-SPE2DB25FEGBL
- Not listed
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $12,839.36 to AmerisourceBergen Drug Corp for the supply of Otezla 30 mg tablets (60-count units) under a firm fixed price contract. The award was issued on August 28, 2025, with an ultimate completion date of August 29, 2025, and represents a non-set-aside competitive procurement. Performance will be executed from the vendor's location in Conshohocken, Pennsylvania, which serves as AmerisourceBergen's corporate...
- The Defense Logistics Agency (DLA) awarded a $10,948.05 delivery order to AmerisourceBergen Drug Corp for 60 tablets of Otezla 30 mg on July 14, 2025, with an ultimate completion date of July 15, 2025. This competitively awarded, non-set-aside contract employs firm fixed-price pricing and represents a single delivery order under AmerisourceBergen's broader pharmaceutical supply relationship with the federal government. The place of performance is listed as Conshohocken, Pennsylvania, which...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $9,444.54 to AmerisourceBergen Drug Corp for the supply of Otezla 30 mg tablets (60-count units) under a firm fixed price contract. The award was made on August 25, 2025, with an ultimate completion date of August 26, 2025, and represents a competitively awarded, non-set-aside procurement. The place of performance is listed as AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This delivery order is issued...
- The Defense Logistics Agency awarded a $19,860.97 delivery order to AmerisourceBergen Drug Corp for the supply of Otezla 30 mg tablets (60-count units) on June 26, 2025, with completion expected by June 27, 2025. This firm fixed-price contract represents a non-competitive set-aside and reflects AmerisourceBergen's critical role as a pharmaceutical distributor supporting federal medical procurement needs. The order is being performed at the contractor's corporate office location in...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $2,574.60 to AmerisourceBergen Drug Corp for the supply of Otezla 30 mg tablets (60-count units) on April 21, 2025, with an ultimate completion date of April 22, 2025. This non-set-aside contract utilizes firm fixed-price pricing and represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), which is valued at $999.99 billion and extends...
- The Defense Logistics Agency awarded a delivery order valued at $5,976.54 to AmerisourceBergen Drug Corp for the supply of Otezla 30 mg tablets (60-count units) on August 12, 2025, with an ultimate completion date of August 13, 2025. This contract is structured as a firm fixed-price delivery order with no set-aside designation, indicating it was competitively awarded. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $3,436.87 to AmerisourceBergen Drug Corp for the supply of Otezla 30 mg tablets (60-count units) under a firm fixed price contract. The order, issued on August 20, 2025, with an ultimate completion date of August 21, 2025, represents a non-competitive set-aside delivery order for pharmaceutical products to support federal medical supply requirements. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania,...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on September 24, 2025, for the supply of Otezla 30 mg tablets (60-count units) under a firm fixed-price contract with a ceiling value of $17,122.81. This is a non-set-aside competitive award with an ultimate completion date of September 25, 2025. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor serving federal medical procurement needs,...
- The Defense Logistics Agency awarded a $31,530.56 delivery order to AmerisourceBergen Drug Corp on July 25, 2025, for the supply of Otezla 30 mg tablets (60-count packages). This is a firm fixed-price, competitively awarded contract with no set-aside designation and an ultimate completion date of July 28, 2025. The delivery order is being fulfilled from AmerisourceBergen's place of performance in Conshohocken, Pennsylvania, where the company maintains its corporate headquarters and primary...
- The Defense Logistics Agency awarded a delivery order valued at $16,991.63 to AmerisourceBergen Drug Corp for the supply of Otezla 30 mg tablets (60-count units). This competitively awarded, non-set-aside contract utilizes firm fixed pricing and carries an ultimate completion date of September 15, 2025. The delivery order was issued on September 12, 2025, with performance to take place at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This delivery order is executed under...
- SPE2DB24D2205Indefinite Delivery Contract
- SPE2DB24D2205-SPE2DB25FEGBLDelivery Order
The Defense Logistics Agency (DLA) awarded a delivery order valued at $26,932.84 to AmerisourceBergen Drug Corp for the supply of Otezla 30 mg tablets (60-count units) on August 11, 2025, with an ultimate completion date of August 12, 2025. This firm fixed-price delivery order represents a competitive award with no set-aside designation. The contract will be performed at AmerisourceBergen's Corporate Office location in Conshohocken, Pennsylvania, where the company maintains its primary operations as a major pharmaceutical distributor serving federal healthcare systems. This delivery order is issued under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) designated SPE2DX with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. The IDC serves as a comprehensive global pharmaceutical support vehicle enabling the company to supply a wide range of pharmaceutical products and medical commodities to support military healthcare programs. AmerisourceBergen's role as a prime vendor reflects its established capability to meet federal procurement requirements through open competition and deliver critical pharmaceutical supplies to the Defense Health Agency and other government healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $26.9k | 8/11/25 |